海外の治験の状況「前立腺癌」での検索結果
161件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Recruiting
- The role of intra-operative flow rate during prostate resection
- benign prostatic hyperplasia;Prostate cancer; br>benign prostatic hyperplasia Prostate cancer;Surgery - Surgical techniques;Cancer - Prostate;Renal and Urogenital - Other renal and urogenital disorders
- New Zealand
- 2018-12-05
Not Recruiting
- Double-blind Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Metastases in Men With Hormone-refractory Prostate Cancer
- Metastatic castrate-resistant prostate cancer br>MedDRA version: 14.0 Level: LLT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Costa Rica, Czech Republic, Denmark, Estonia, European Union, Finland, Germany, Greece, Hungary, India, Israel, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Panama, Peru, Russian Federation, South Africa, Spain, Sweden, Switzerland, Turkey, Ukraine, United Kingdom, United States
- 2006-03-31
Recruiting
- Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
- Metastatic Breast Cancer;Metastatic Prostate Cancer;Bone Metastases
- Austria, Germany, Switzerland
- 2014-01-29
Authorised
- Randomized phase II CAbazitaxel dose Individualization and Neutropenia prevention TriAl (CAINTA)
- Stage II with advanced Castration-Resistant Prostate Cancer (CRPC);Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Germany, Switzerland
- 2014-06-03
Recruiting
- [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)
- Breast Cancer;Prostate Cancer;Colorectal Cancer;Non Small Cell Lung Cancer;Small Cell Lung Cancer
- Austria, France, Netherlands
- 2018-10-21
Not recruiting
- Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
- Hormone Refractory Prostate Cancer;Hormone Refractory Prostate Cancer;Hormone Refractory Prostate Cancer;Hormone Refractory Prostate Cancer
- Argentina, Australia, Belgium, Brazil, Bulgaria, Canada, Czech Republic, Finland, Former Serbia and Montenegro, France, Germany, Hungary, India, Ireland, Italy, Latvia, Lithuania, Mexico, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Russian Federation, Serbia, Slovakia, South Africa, Spain, Switzerland, Ukraine, United Kingdom, United States
- 2006-02-02
Authorised
- MULTICENTRE, SINGLE-ARM, OPEN LABEL CLINICAL TRIAL INTENDED TO PROVIDE EARLY ACCESS TO CABAZITAXEL IN PATIENTS WITH METASTATIC HORMONE REFRACTORY PROSTATE CANCER PREVIOUSLY TREATED WITH A DOCETAXEL-CONTAINING REGIMEN AND TO DOCUMENT SAFETY OF CABAZITAXEL IN THESE PATIENTS
- Metastatic hormone refractory prostate cancer previously treated with a docetaxel-containing regimen MedDRA version: 14.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Canada, China, Croatia, Czech Republic, Denmark, Finland, Hungary, India, Ireland, Italy, Malaysia, Mexico, Philippines, Portugal, Singapore, Spain, Sweden, Taiwan, United Kingdom
- 2010-10-08
Not recruiting
- Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
- Febrile Neutropenia;Cancer;Breast Cancer;Ovarian Cancer;Lung Cancer;Prostate Cancer;Multiple Myeloma;Bladder Cancer;B-cell Lymphoma;Febrile Neutropenia;Cancer;Breast Cancer;Ovarian Cancer;Lung Cancer;Prostate Cancer;Multiple Myeloma;Bladder Cancer;B-cell Lymphoma;Febrile Neutropenia;Cancer;Breast Cancer;Ovarian Cancer;Lung Cancer;Prostate Cancer;Multiple Myeloma;Bladder Cancer;B-cell Lymphoma;Febrile Neutropenia;Cancer;Breast Cancer;Ovarian Cancer;Lung Cancer;Prostate Cancer;Multiple Myeloma;Bladder Cancer;B-cell Lymphoma
- Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, Poland, Romania, Spain, Switzerland, United Kingdom
- 2011-08-30
Not Recruiting
- Sipuleucel-T Manufacturing Demonstration Study
- metastatic castrate resistant prostate cancer br>MedDRA version: 14.1 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: LLT Classification code 10036910 Term: Prostate cancer NOS System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: LLT Classification code 10036916 Term: Prostate cancer stage D System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 14.1 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Austria, Netherlands, United Kingdom
- 2011-11-17
Not Recruiting
- A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)
- Cancer, Prostate;C61 - Malignant neoplasm of prostate
- Austria, Belgium, France, Germany, Spain, United Kingdom, United States
- 2015-11-12